1. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997;158:481–487.
2. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. J Urol 1999; 162: 1301–6.
3. Roehrborn C, Fuh V, Ruane P et al. The relationship between total and free PSA, prostate volume and age in men age 40–60 with no clinical diagnosis of benign prostatic hyperplasia necessitating therapy. J Urol 2000; 163 (Suppl.): 252A.
4. EAU Recommendations on Benign Prostatic Hyperplasia. Update 2009. (Eds. J. de la Rosette et al). http://www.uroweb.org/fileadmin/user_upload/Guidelines/BPH.pdf
5. Price D. Potential mechanisms of action of superselective alpha-1-adrenoreceptor antagonists. Eur Urol 2001; 40 (Suppl. 4): 5–11.
6. Djavan B, Chapple C, Milani S, Marberger M. State of art on the efficacy and tolerability of alpha-1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of BPH. Urology 2004; 64: 1080–81.
7. Farmer R, Hutchinson A, Chapple R. Comparison of the treatment regimes on new and existing LUTS/BPH patients in 6 European countries. Eur Urol Suppl 2004; 3: 60 (abs 230).
8. Forray C, Noble SA. Subtype selective α1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 1999; 8 (12): 2073–94.
9. Madersbacher S, Merszalk M, Lackner J et al. The long term outcome of medical therapy for BPH. Eur Urol 2007; 51: 1522–33.
10. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha-1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081–8.
11. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prosatic hyperplasia. N Engl J Med 2003; 349: 2387–98.
12. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003; 170: 498–502.
13. Lepor H. Terazosin research group/Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406–13.
14. Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 2000; 38: 2–19.
15. Kaplan SA, McConnell JD, Roehrborn CG et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with urinary tract symptoms and baseline total prostate volume of 25 ml or greater. J Urol 2006; 175: 217–20.
16. Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride tamsulosin, and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-yr results from the CombAT study. J Urol 2008; 179: 616–21.
17. Crawford ED, Wilson SS, McConnel JD et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175: 1422–6.
18. Kaplan SA, Roehrborn CG, Ronver ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: randomized controlled trial. JAMA 2006; 296: 2319–28.
19. Athansopoulos A, Gyftopoulos K, Giannitsas K et al. Combination treatment with an alpha-blocker plus an anticholinergic foe bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253–6.
20. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–49.
21. Kaplan SA, Gonsalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2008; 53: 1320.